Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Calsed amrubicin: Interim Phase II data

Interim data from an open-label, U.S. Phase II trial showed that 11 of 28 patients (39%) receiving amrubicin had a

Read the full 207 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE